Statera BioPharma 

Statera BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing cutting-edge immunotherapies. These novel treatments aim to address a range of serious conditions, including autoimmune disorders, neutropenia, anemia, emerging viral infections, and various cancers. This development is underpinned by a proprietary technological platform engineered to restore the body's immune system balance and re-establish overall physiological homeostasis. The company's therapeutic strategies are designed to directly stimulate patients' immune systems, specifically eliciting antigen-specific killer T-cells and antibodies to activate crucial defenses against inflammatory, infectious, and cancerous diseases. Statera BioPharma's clinical pipeline features programs such as STAT-201 for Crohn's disease, Entolimod for hematological conditions, STAT-401 for pancreatic cancer, and STAT-205 for COVID-19. The company is also actively exploring therapeutic applications for fibromyalgia and multiple sclerosis. Formerly known as Cytocom, Inc., the company officially adopted the name Statera BioPharma, Inc. in September 2021. Its operations are headquartered in Fort Collins, Colorado.